Literature DB >> 21896369

The size and burden of mental disorders and other disorders of the brain in Europe 2010.

H U Wittchen1, F Jacobi, J Rehm, A Gustavsson, M Svensson, B Jönsson, J Olesen, C Allgulander, J Alonso, C Faravelli, L Fratiglioni, P Jennum, R Lieb, A Maercker, J van Os, M Preisig, L Salvador-Carulla, R Simon, H-C Steinhausen.   

Abstract

AIMS: To provide 12-month prevalence and disability burden estimates of a broad range of mental and neurological disorders in the European Union (EU) and to compare these findings to previous estimates. Referring to our previous 2005 review, improved up-to-date data for the enlarged EU on a broader range of disorders than previously covered are needed for basic, clinical and public health research and policy decisions and to inform about the estimated number of persons affected in the EU.
METHOD: Stepwise multi-method approach, consisting of systematic literature reviews, reanalyses of existing data sets, national surveys and expert consultations. Studies and data from all member states of the European Union (EU-27) plus Switzerland, Iceland and Norway were included. Supplementary information about neurological disorders is provided, although methodological constraints prohibited the derivation of overall prevalence estimates for mental and neurological disorders. Disease burden was measured by disability adjusted life years (DALY).
RESULTS: Prevalence: It is estimated that each year 38.2% of the EU population suffers from a mental disorder. Adjusted for age and comorbidity, this corresponds to 164.8million persons affected. Compared to 2005 (27.4%) this higher estimate is entirely due to the inclusion of 14 new disorders also covering childhood/adolescence as well as the elderly. The estimated higher number of persons affected (2011: 165m vs. 2005: 82m) is due to coverage of childhood and old age populations, new disorders and of new EU membership states. The most frequent disorders are anxiety disorders (14.0%), insomnia (7.0%), major depression (6.9%), somatoform (6.3%), alcohol and drug dependence (>4%), ADHD (5%) in the young, and dementia (1-30%, depending on age). Except for substance use disorders and mental retardation, there were no substantial cultural or country variations. Although many sources, including national health insurance programs, reveal increases in sick leave, early retirement and treatment rates due to mental disorders, rates in the community have not increased with a few exceptions (i.e. dementia). There were also no consistent indications of improvements with regard to low treatment rates, delayed treatment provision and grossly inadequate treatment. Disability: Disorders of the brain and mental disorders in particular, contribute 26.6% of the total all cause burden, thus a greater proportion as compared to other regions of the world. The rank order of the most disabling diseases differs markedly by gender and age group; overall, the four most disabling single conditions were: depression, dementias, alcohol use disorders and stroke.
CONCLUSION: In every year over a third of the total EU population suffers from mental disorders. The true size of "disorders of the brain" including neurological disorders is even considerably larger. Disorders of the brain are the largest contributor to the all cause morbidity burden as measured by DALY in the EU. No indications for increasing overall rates of mental disorders were found nor of improved care and treatment since 2005; less than one third of all cases receive any treatment, suggesting a considerable level of unmet needs. We conclude that the true size and burden of disorders of the brain in the EU was significantly underestimated in the past. Concerted priority action is needed at all levels, including substantially increased funding for basic, clinical and public health research in order to identify better strategies for improved prevention and treatment for disorders of the brain as the core health challenge of the 21st century.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2011        PMID: 21896369     DOI: 10.1016/j.euroneuro.2011.07.018

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  903 in total

Review 1.  Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety.

Authors:  Xia Chen; Joop van Gerven; Adam Cohen; Gabriel Jacobs
Journal:  Acta Pharmacol Sin       Date:  2018-12-05       Impact factor: 6.150

Review 2.  Utility scores for different health states related to depression: individual participant data analysis.

Authors:  Spyros Kolovos; Judith E Bosmans; Johanna M van Dongen; Birre van Esveld; Dorcas Magai; Annemieke van Straten; Christina van der Feltz-Cornelis; Kirsten M van Steenbergen-Weijenburg; Klaas M Huijbregts; Harm van Marwijk; Heleen Riper; Maurits W van Tulder
Journal:  Qual Life Res       Date:  2017-03-04       Impact factor: 4.147

Review 3.  A Review of the Clinical Utility of Systematic Behavioral Observations in Attention Deficit Hyperactivity Disorder (ADHD).

Authors:  Franziska Minder; Agnieszka Zuberer; Daniel Brandeis; Renate Drechsler
Journal:  Child Psychiatry Hum Dev       Date:  2018-08

4.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

5.  Common Sleep, Psychiatric, and Somatic Problems According to Work Schedule: an Internet Survey in an Eastern European Country.

Authors:  Bogdan I Voinescu
Journal:  Int J Behav Med       Date:  2018-08

6.  Coping Strategies Mediate the Effect of Stressful Life Events on Schizotypal Traits and Psychotic Symptoms in 22q11.2 Deletion Syndrome.

Authors:  Marco Armando; Corrado Sandini; Maelle Chambaz; Marie Schaer; Maude Schneider; Stephan Eliez
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

7.  Is the effect of work-related psychosocial exposure on depressive and anxiety disorders short-term, lagged or cumulative?

Authors:  Stéphanie Boini; Martin Kolopp; Michel Grzebyk; Guy Hédelin; Dominique Chouanière
Journal:  Int Arch Occup Environ Health       Date:  2019-08-03       Impact factor: 3.015

8.  Cadherin 13: human cis-regulation and selectively-altered addiction phenotypes and cerebral cortical dopamine in knockout mice.

Authors:  Jana Drgonova; Donna Walther; G Luke Hartstein; Mohammad O Bukhari; Michael H Baumann; Jonathan Katz; Frank Scott Hall; Elizabeth R Arnold; Shaun Flax; Anthony Riley; Olga Rivero-Martin; Klaus-Peter Lesch; Juan Troncoso; Barbara Ranscht; George R Uhl
Journal:  Mol Med       Date:  2016-08-18       Impact factor: 6.354

Review 9.  Digitally Delivered Psychological Interventions for Anxiety Disorders: a Comprehensive Review.

Authors:  Evgenia Stefanopoulou; David Lewis; Matthew Taylor; James Broscombe; Jan Larkin
Journal:  Psychiatr Q       Date:  2019-03

10.  Maternal psychopathology and mental health treatment delay in adolescents from a national cohort.

Authors:  Esther Stalujanis; Gunther Meinlschmidt; Angelo Belardi; Marion Tegethoff
Journal:  Health Serv Res       Date:  2018-11-28       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.